Articles From: Synchrony Financial’s Optimizer+plus Takes Top Advertising Effectiveness Awards to Synopsys DesignWare USB 3.0 IP Shipped in More Than 100 Million Production SoCs


Synchrony Financial (NYSE:SYF), one of the nation’s premier consumer financial services companies, has earned six Platinum and Silver awards in the 2014 Summit Marketing Effectiveness Award (Summit MEA) competition for multiple marketing communication initiatives for its Optimizer +plus branded, FDIC-insured savings products through Synchrony Bank.
Sign-up for Synchrony Financial’s Optimizer+plus Takes Top Advertising Effectiveness Awards investment picks
Synchrony Financial (NYSE: SYF ), a premier consumer financial services company with 80 years of retail heritage, and its People with Disabilities Network (PDN) hosted an employee and community partner event on November 5 to raise awareness of promoting employment for persons with disabilities in Kettering, Ohio.
Sign-up for Synchrony Financial’s People with Disabilities Network Hosts Community Event investment picks
http://media.marketwire.com/attachments/201202/21296_SURGLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1151453&ProfileId=051205&sourceType=1 O'FALLON, MO --
Sign-up for Synergetics Reports Fourth Quarter and Fiscal Year 2014 Results investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the full exercise of the over-allotment option granted to the initial purchasers to purchase an additional $25 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019 in connection with its previously announced $175 million Convertible Senior Note offering, bringing total gross proceeds from the offering to $200 million (before deducting the initial purchasers’ discount and other offering expenses payable by the Company). The offering (including the over-allotment option) is expected to close on or about November 3, 2014, subject to customary closing conditions.
Sign-up for Synergy Pharmaceuticals Inc. Announces Full Exercise of Over-Allotment Option investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the closing of its previously announced private offering of $200 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019 (including the full exercise of the over-allotment option granted to the initial purchasers to purchase an additional $25 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019). The notes are unsecured, senior obligations of Synergy and bear interest at a rate of 7.50% per year, payable semiannually in arrears on May 1 and November 1 of each year, beginning on May 1, 2015.
Sign-up for Synergy Pharmaceuticals Inc. Announces Issuance of $200 Million of 7.50% Convertible Senior Notes investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019.
Sign-up for Synergy Pharmaceuticals Inc. Announces Pricing of Private Offering of $175 Million of 7.50% Convertible Senior Notes investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) (the “Company”), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that it is offering to sell up to $150 million principal amount of its convertible senior notes due 2019 (the “notes”) through a private offering.
Sign-up for Synergy Pharmaceuticals Inc. Announces Private Offering of Convertible Senior Notes investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the presentation of results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 adult patients (mITT population= 423) with irritable bowel syndrome with constipation (IBS-C). Data presented at ACG demonstrate that plecanatide, once-daily oral tablet, significantly improved complete spontaneous bowel movement (CSBM) frequency, bowel habits, treatment satisfaction and significantly reduced abdominal pain in patients with IBS-C throughout the 12 week treatment period.
Sign-up for Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has reached the halfway mark for total enrollment in the second pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation (CIC). The trial is currently being conducted at 180 sites and has randomized over 675 CIC patients.
Sign-up for Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), today reported its financial results and business update for the three and nine months ended September 30, 2014.
Sign-up for Synergy Pharmaceuticals Reports Third Quarter 2014 Financial Results investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it will present additional positive data from a phase 2b study assessing plecanatide’s efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C). The data will be presented during a plenary session at the American College of Gastroenterology’s 2014 Annual Scientific Meeting in Philadelphia, Pennsylvania on October 20, 2014.
Sign-up for Synergy Pharmaceuticals to Present Additional Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation at ACG 2014 Annual Scientific Meeting investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and Chief Executive Officer, Dr.
Sign-up for Synergy Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference investment picks
IBM Among Top 3 Cloud Providers ARMONK, N.Y. , Nov.
Sign-up for Synergy Research Ranks IBM as the #1 Hybrid Cloud Provider for the Enterprise investment picks
YOKNEAM, Israel , Sept.
Sign-up for Syneron Announces Details for Upcoming Investor Meeting investment picks
New Device Featured at the European Academy of Dermatology and Venereology* WAYLAND, Massachusetts , October 8, 2014 /PRNewswire/ -- Syneron Medical Ltd.
Sign-up for Syneron Announces Launch of PicoWay Picosecond Device for Pigmented Lesion Treatment and Tattoo Removal investment picks
Syneron Candela Announces FDA Clearance of PicoWay Picosecond Laser for Tattoo Removal Canada NewsWire The Dual Wavelength PicoWay ® Laser will be launched immediately in the US and featured at The American Society of Dermatologic Surge ry Meeting, San Diego , November 6-9 WAYLAND, MA , Nov.
Sign-up for Syneron Candela Announces FDA Clearance of PicoWay Picosecond Laser for Tattoo Removal investment picks
The Dual Wavelength PicoWay® Laser will be launched immediately in the US and featured at The American Society of Dermatologic Surgery Meeting, San Diego, November 6-9 WAYLAND, Mass.
Sign-up for Syneron Candela Announces FDA Clearance of PicoWay Picosecond Laser for Tattoo Removal investment picks
Fungus Indication Expands Functionality of Gentle Pro Laser Series IRVINE, Calif.
Sign-up for Syneron Medical Introduces New FDA-Cleared 5mm Spot Size for Treatment of Onychomycosis investment picks
YOKNEAM, Israel , Oct.
Sign-up for Syneron Medical to Report Third Quarter 2014 Financial Results on November 12, 2014 investment picks
YOKNEAM, Israel , Sept.
Sign-up for Syneron's elure™ Wins Allure Magazine's BEST OF BEAUTY Award For The Fourth Consecutive Year investment picks
SYNNEX Corporation (NYSE: SNX), a leading business process services company, today announced that its Board of Directors has approved the initiation of a quarterly cash dividend to shareholders of its common stock.
Sign-up for SYNNEX Corporation Initiates Quarterly Cash Dividend investment picks
SYNNEX Corporation (NYSE: SNX), a leading business process services company, today announced financial results for the fiscal third quarter ended August 31, 2014.
Sign-up for SYNNEX Corporation Reports Fiscal 2014 Third Quarter Results investment picks
SYNNEX Corporation (NYSE:SNX), a leading business process services company, will announce fiscal third quarter results for the period ended August 31, 2014 after market close on Monday, September 29, 2014.
Sign-up for SYNNEX Corporation to Announce Fiscal Third Quarter Results on September 29, 2014 investment picks
Synnex Corp.
Sign-up for Synnex shares rise on earnings beat, outlook investment picks
Synopsys Synplify Pro Synthesis Tool Delivers Superior Quality of Results for Users of Gowin Semiconductor FPGAs MOUNTAIN VIEW, Calif.
Sign-up for Synopsys and Gowin Semiconductor Ink Multi-Year OEM Agreement for FPGA Design Software investment picks
Silicon-Proven, Reprogrammable NVM IP Delivers Smallest Area for Calibration and Trimming Applications MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Announces Availability of DesignWare Non-Volatile Memory IP for TowerJazz 180-nm Process Technology investment picks
Single, unified Liberty variation format standardized by the IEEE Industry Standards Board MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Announces New Additions to Liberty to Significantly Speed up Timing Closure investment picks
2014/8/25
Annual Competition Recognizes Student Achievements in Optical Design MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Announces Results of Robert S. Hilbert Memorial Optical Design Competition investment picks
Use of Silicon-Proven DesignWare USB IP by More than 60 Companies Demonstrates High Quality and Low Integration Risk MOUNTAIN VIEW, Calif.
Sign-up for Synopsys DesignWare USB 3.0 IP Shipped in More Than 100 Million Production SoCs investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Synchrony Financial’s Optimizer+plus Takes Top Advertising Effectiveness Awards to Synopsys DesignWare USB 3.0 IP Shipped in More Than 100 Million Production SoCs
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent